Clinical trials
Alopecia clinical trials
Below are recruiting alopecia clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07012486RecruitingEarly Phase 1
Dihydroartemisinin for female hair loss
This trial tests if dihydroartemisinin, a medicine derived from a plant, can help treat female pattern hair loss. It may be an option for women who haven't used other hair loss treatments recently.
Shanghai, Shanghai MunicipalityAges 18–40 - NCT06946550Recruiting
Laser treatment for scarring hair loss with gene study
This trial tests if a non-ablative laser can help treat scarring alopecia (a type of hair loss where follicles are replaced by scar tissue). Researchers will also study your hair follicles' genes to understand how the laser works. It may be an option if your hair loss has been stable for at least 3 months.
Elmsford, New YorkAges 18 years+ - NCT06916793RecruitingPhase 3
Study of a new hair loss treatment for men
This study tests an experimental medication (CKD-843) for men with male pattern baldness. It aims to see if the treatment is safe and effective for regrowing hair.
SeoulAges 18–50 - NCT06873945RecruitingPhase 3
Study of two doses of ritlecitinib for alopecia areata
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
Birmingham, AlabamaAges 12 years+ - NCT06826196RecruitingPhase 1/Phase 2
Testing a new shot for patchy hair loss (alopecia areata)
This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.
Thousand Oaks, CaliforniaAges 18–55 - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+ - NCT06562270Recruiting
Teens with severe alopecia areata: treatment safety study
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
Waltham, MassachusettsAges 12–17 - NCT06327581Recruiting
Microneedling with creams for patchy hair loss
This trial tests if microneedling with either lactic acid, vitamin D3, or a steroid cream helps regrow hair in people with patchy alopecia areata (small bald spots).
ZagazigAges 16 years+ - NCT06104839RecruitingPhase 2
Oral NXC-736 for moderate to severe alopecia areata
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
SeoulAges 19–65 - NCT06012240RecruitingPhase 3
Testing Upadacitinib for Severe Alopecia Areata
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Birmingham, AlabamaAges 12–63 - NCT05866562RecruitingPhase 2
Dupilumab for hair regrowth in kids with alopecia areata
This trial studies dupilumab (an injection medicine) to help grow hair in children and teens with alopecia areata, an autoimmune hair-loss condition. It aims to see whether the treatment improves hair regrowth compared with usual care over the study period.
Irvine, CaliforniaAges 6–17 - NCT05745389Recruiting
Alopecia areata registry to track treatment safety and results
This registry collects information from adults with alopecia areata who are starting or taking certain approved medications. It helps researchers understand how well these treatments work and how safe they are in real-world care.
Waltham, MassachusettsAges 18 years+ - NCT04594018RecruitingPhase 3
Test a hair lotion for male pattern hair loss
This Phase 3 study tests whether a specific hair lotion works and is safe for men with male pattern hair loss. It also checks that results are consistent while you keep similar hair care and avoid certain other hair-loss treatments.
Osasco, São PauloAges 18–60 - NCT05417308RecruitingEarly Phase 1
Minoxidil for hair loss from breast cancer hormone therapy
This early-phase study tests whether using minoxidil as a lotion (topical) or by mouth (oral) can improve hair loss caused by breast cancer hormone (endocrine) therapy. It may help you keep or regrow hair while continuing your cancer treatment.
Columbus, OhioAges 18 years+ - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT04764357Recruiting
Scalp cooling to help prevent chemotherapy-related hair loss in kids
This study looks at whether “cold cap” scalp cooling can help prevent or reduce hair loss in children getting chemotherapy. It’s aimed at kids treated with certain chemotherapy medicines and who may be at risk for losing their hair.
Memphis, TennesseeAges 7 years+ - NCT04764331Recruiting
Red light cap for scar-forming hair loss in women
This pilot study tests an “all LED” red light cap to treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss. If you’re a woman with confirmed CCCA at Stage II–III and stable treatment, the study may help see whether red light can improve your hair loss without changing your current plan.
Winston-Salem, North CarolinaAges 18–75 - NCT04207931RecruitingPhase 4
Study of treatments for a specific scar-ring hair loss
This study looks at treatment results for central centrifugal cicatricial alopecia (CCCA), a type of hair loss that causes scarring and permanent hair loss. It will follow African-American women to see how well treatments work for different levels of severity.
Winston-Salem, North CarolinaAges 18–60 - NCT03976622Enrolling by invitation
Inflammation study in vitiligo and other skin conditions
This study looks at inflammation in people with vitiligo, psoriasis, atopic dermatitis, or alopecia areata. It aims to understand how these conditions compare, which may lead to better treatments.
Bordeaux, BordeauxAges 18–75 - NCT07819435RecruitingPhase 2/Phase 3
Topical treatment for male pattern hair loss
This study tests an investigational topical medication called PP405 for male pattern hair loss. It aims to see if the treatment is safe and effective for regrowing hair in men with moderate balding.
Birmingham, AlabamaAges 18–55 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT05938569Recruiting
Test of ARTAS computer-assisted hair restoration for men
This study looks at a computer-guided system (ARTAS) to move hair follicles to thinning areas to treat male pattern hair loss. You might join if you’re a man with moderate thinning and can follow the study’s hair-cutting and follow-up steps.
Los Altos, CaliforniaAges 20–70 - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT07734870RecruitingPhase 2
Tirzepatide for treating scarring hair loss (CCCA)
This study tests whether tirzepatide (Mounjaro) can help treat a specific type of scarring hair loss called CCCA. It is for people whose hair loss is still active and who are not taking diabetes or weight-loss medications.
Baltimore, MarylandAges 18–80
Hear when a new Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alopecia?
- Yes. Clin2 currently lists 82 recruiting alopecia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alopecia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alopecia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.